Collectively, this shows that FGFR1 overexpression plays a central role in EGFR-TKI resistance across multiple EGFR-TKI-resistant NSCLC cell line models, but the growth inhibition by combined FGFRi and EGFR-TKI seems to be inconsistent between different FGFR1-overexpressing EGFR-TKI resistance models, and thus this combination might not be optimal to overcome EGFR-TKI resistance in all FGFR1-expressing NSCLC tumors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.